Georgia Patent of the Month – May 2023
Genexa Inc., the world’s first and only clean medicine pharmaceutical company, is revolutionizing the field of pediatric medicine by offering a clean and natural alternative to conventional pharmaceutical syrups. While it is often easier to give sick children medicine in the form of a syrup instead of a tablet, these syrups often taste terrible due to the presence of active pharmaceutical agents. Other pharmaceutical chemists have turned to artificial ingredients to mask the taste, but Genexa’s revolutionary formula is composed primarily of natural ingredients, including agave syrup and other inactive ingredients that are gluten-free, non-GMO, and certified vegan.
One of the major advantages of Genexa’s syrup formulation is that it can be tailored to the child’s body weight, making it easier to administer the correct dose. Between the improved flavor profiles and the low viscosity, the medicine is more likely to be accepted by a young child, improving intake and compliance.
Genexa’s pharmaceutical suspension can enhance the taste masking of unpalatable pharmaceutical active agents with generally natural ingredients. They exclude unnatural ingredients such as aspartame, carbomer, EDTA, gelatin, milk, parabens, polyethylene glycol, titanium dioxide, and other unnatural ingredients, and instead use clean inactive ingredients that are gluten-free, non-GMO, and certified vegan. Genexa’s suspensions are made with the same active ingredients needed for treatment but without artificial ingredients. This allows parents to provide their children with the medication they need without introducing artificial ingredients.
These pharmaceutical suspensions can be used with various active pharmaceutical agents, including acetaminophen, ibuprofen, famotidine, pseudoephedrine, hydrochloride, chlorpheniramine maleate, dextromethorphan hydrobromide, guaifenesin, diphenhydramine hydrochloride, loperamide hydrochloride, and simethicone and suitable combinations thereof. This makes the product a versatile solution that can be used for a variety of pediatric ailments.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.